Banque Pictet & Cie SA Purchases 17,282 Shares of Johnson & Johnson (NYSE:JNJ)

Banque Pictet & Cie SA lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 10.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 178,474 shares of the company's stock after purchasing an additional 17,282 shares during the period. Banque Pictet & Cie SA's holdings in Johnson & Johnson were worth $25,811,000 as of its most recent filing with the SEC.

Other large investors also recently added to or reduced their stakes in the company. IFS Advisors LLC grew its holdings in shares of Johnson & Johnson by 138.9% in the fourth quarter. IFS Advisors LLC now owns 172 shares of the company's stock worth $25,000 after purchasing an additional 100 shares during the last quarter. Highline Wealth Partners LLC purchased a new position in shares of Johnson & Johnson in the third quarter valued at about $31,000. RPg Family Wealth Advisory LLC bought a new position in shares of Johnson & Johnson during the third quarter valued at about $35,000. Bay Harbor Wealth Management LLC bought a new stake in shares of Johnson & Johnson in the 4th quarter worth approximately $32,000. Finally, Mowery & Schoenfeld Wealth Management LLC increased its stake in shares of Johnson & Johnson by 58.7% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company's stock valued at $40,000 after buying an additional 91 shares during the period. Hedge funds and other institutional investors own 69.55% of the company's stock.

Analyst Ratings Changes

Several analysts recently weighed in on JNJ shares. Leerink Partners cut their price target on shares of Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating on the stock in a report on Thursday, January 23rd. Bank of America lowered their target price on Johnson & Johnson from $160.00 to $159.00 and set a "neutral" rating for the company in a research note on Thursday, January 23rd. StockNews.com raised Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, January 25th. Royal Bank of Canada restated an "outperform" rating and set a $181.00 target price on shares of Johnson & Johnson in a report on Wednesday. Finally, Guggenheim increased their price target on shares of Johnson & Johnson from $162.00 to $166.00 and gave the stock a "neutral" rating in a research note on Monday, February 3rd. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and a consensus price target of $170.67.

Remove Ads

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Timothy Schmid sold 403 shares of the company's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now directly owns 15,098 shares in the company, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Mark A. Weinberger acquired 1,000 shares of the firm's stock in a transaction on Thursday, December 12th. The stock was purchased at an average cost of $147.22 per share, with a total value of $147,220.00. Following the purchase, the director now owns 1,000 shares of the company's stock, valued at $147,220. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ traded up $2.67 during midday trading on Friday, hitting $162.35. The company had a trading volume of 12,540,171 shares, compared to its average volume of 9,073,381. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $168.85. The company has a fifty day moving average of $148.93 and a two-hundred day moving average of $155.90. The company has a market cap of $390.87 billion, a price-to-earnings ratio of 24.41, a PEG ratio of 2.53 and a beta of 0.52. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business's revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter last year, the company earned $2.29 earnings per share. On average, equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.06%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson's payout ratio is currently 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.